MoonLake Immunotherapeutics (MLTX) EBITDA (2021 - 2026)

MoonLake Immunotherapeutics' EBITDA history runs 6 years deep, the most recent figure standing at -$70.0 million for Q1 2026.

• In Q1 2026, EBITDA fell 61.94% year-over-year to -$70.0 million; the TTM figure through Mar 2026 stood at -$261.6 million (down 77.13% YoY), while the FY2025 annual figure was -$234.8 million, down 97.9% from the prior year.
• EBITDA was -$70.0 million for Q1 2026 at MoonLake Immunotherapeutics, down from -$62.7 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$8.1 million in Q3 2023 to a low of -$70.9 million in Q3 2025.
• Historically, EBITDA has averaged -$30.5 million across 5 years, with a median of -$17.3 million in 2022.
• Biggest YoY gain for EBITDA was 68.54% in 2022; the steepest drop was 16491.79% in 2022.
• A 5-year view of EBITDA shows it stood at -$16.9 million in 2022, then soared by 50.29% to -$8.4 million in 2023, then slumped by 425.18% to -$44.2 million in 2024, then sank by 41.87% to -$62.7 million in 2025, then slipped by 11.63% to -$70.0 million in 2026.
• The last three EBITDA figures came in at -$70.0 million (Q1 2026), -$62.7 million (Q4 2025), and -$70.9 million (Q3 2025), per Business Quant data.